Literature DB >> 21838732

Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time.

Stuart G Baker1, Daniel J Sargent, Marc Buyse, Tomasz Burzykowski.   

Abstract

Using multiple historical trials with surrogate and true endpoints, we consider various models to predict the effect of treatment on a true endpoint in a target trial in which only a surrogate endpoint is observed. This predicted result is computed using (1) a prediction model (mixture, linear, or principal stratification) estimated from historical trials and the surrogate endpoint of the target trial and (2) a random extrapolation error estimated from successively leaving out each trial among the historical trials. The method applies to either binary outcomes or survival to a particular time that is computed from censored survival data. We compute a 95% confidence interval for the predicted result and validate its coverage using simulation. To summarize the additional uncertainty from using a predicted instead of true result for the estimated treatment effect, we compute its multiplier of standard error. Software is available for download.
© 2011, The International Biometric Society No claim to original US government works.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21838732      PMCID: PMC3218246          DOI: 10.1111/j.1541-0420.2011.01646.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  24 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  On meta-analytic assessment of surrogate outcomes.

Authors:  M H Gail; R Pfeiffer; H C Van Houwelingen; R J Carroll
Journal:  Biostatistics       Date:  2000-09       Impact factor: 5.899

3.  Simultaneous-equation estimation in a clinical trial of the effect of smoking on birth weight.

Authors:  T Permutt; J R Hebel
Journal:  Biometrics       Date:  1989-06       Impact factor: 2.571

4.  A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.

Authors:  Stuart G Baker
Journal:  Biostatistics       Date:  2005-06-22       Impact factor: 5.899

5.  Exploring and validating surrogate endpoints in colorectal cancer.

Authors:  Tomasz Burzykowski; Marc Buyse; Greg Yothers; Junichi Sakamoto; Dan Sargent
Journal:  Lifetime Data Anal       Date:  2008-01-20       Impact factor: 1.588

6.  Extending DerSimonian and Laird's methodology to perform multivariate random effects meta-analyses.

Authors:  Dan Jackson; Ian R White; Simon G Thompson
Journal:  Stat Med       Date:  2010-05-30       Impact factor: 2.373

Review 7.  The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints.

Authors:  Marissa N Lassere
Journal:  Stat Methods Med Res       Date:  2007-10-09       Impact factor: 3.021

8.  Surrogate endpoints in clinical trials: definition and operational criteria.

Authors:  R L Prentice
Journal:  Stat Med       Date:  1989-04       Impact factor: 2.373

9.  The paired availability design: a proposal for evaluating epidural analgesia during labor.

Authors:  S G Baker; K S Lindeman
Journal:  Stat Med       Date:  1994-11-15       Impact factor: 2.373

10.  Surrogate endpoints.

Authors:  S S Ellenberg
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

View more
  7 in total

1.  Surrogate endpoint analysis: an exercise in extrapolation.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2012-12-21       Impact factor: 13.506

2.  Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.

Authors:  Stuart G Baker
Journal:  Stat Med       Date:  2017-11-21       Impact factor: 2.373

3.  Evaluating surrogate endpoints, prognostic markers, and predictive markers: Some simple themes.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  Clin Trials       Date:  2014-11-10       Impact factor: 2.486

4.  Latent class instrumental variables: a clinical and biostatistical perspective.

Authors:  Stuart G Baker; Barnett S Kramer; Karen S Lindeman
Journal:  Stat Med       Date:  2015-08-04       Impact factor: 2.373

5.  The risky reliance on small surrogate endpoint studies when planning a large prevention trial.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2012-06-28       Impact factor: 2.483

6.  A Bayesian prediction model between a biomarker and the clinical endpoint for dichotomous variables.

Authors:  Zhiwei Jiang; Yang Song; Qiong Shou; Jielai Xia; William Wang
Journal:  Trials       Date:  2014-12-20       Impact factor: 2.279

Review 7.  Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments.

Authors:  Christopher J Weir; Rod S Taylor
Journal:  Pharm Stat       Date:  2022-07       Impact factor: 1.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.